Integrin αvβ3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non–small-cell lung cancer models

MLA

Albert, Jeffrey M., et al. “Integrin Αvβ3 Antagonist Cilengitide Enhances Efficacy of Radiotherapy in Endothelial Cell and Non–small-Cell Lung Cancer Models.” International Journal of Radiation Oncology, Biology, Physics, vol. 65, no. 5, Aug. 2006, pp. 1536–43. EBSCOhost, https://doi.org/10.1016/j.ijrobp.2006.04.036.

APA

Albert, J. M., Cao, C., Geng, L., Leavitt, L., Hallahan, D. E., & Lu, B. (2006). Integrin αvβ3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non–small-cell lung cancer models. International Journal of Radiation Oncology, Biology, Physics, 65(5), 1536–1543. https://doi.org/10.1016/j.ijrobp.2006.04.036

Chicago

Albert, Jeffrey M., Carolyn Cao, Ling Geng, Lauren Leavitt, Dennis E. Hallahan, and Bo Lu. 2006. “Integrin Αvβ3 Antagonist Cilengitide Enhances Efficacy of Radiotherapy in Endothelial Cell and Non–small-Cell Lung Cancer Models.” International Journal of Radiation Oncology, Biology, Physics 65 (5): 1536–43. doi:10.1016/j.ijrobp.2006.04.036.